MannKind Corporation (MNKD) Latest News: $40M Financing for Afrezza, Rating Reiterated by Zacks, Price Target & More

Editor’s Note: MannKind Corporation (NASDAQ:MNKD)

MannKind rewarded for positive Afrezza data with $40M financing (FierceBiotech)
MannKind’s positive take on interim Phase III data for its inhaled insulin Afrezza has a big sweetener tied to it. The Valencia, CA-based MannKind Corporation (NASDAQ:MNKD) has picked up a much-needed $40 million financing from Deerfield as a result of the data readout, the second of four tranches slated to provide MannKind with $160 million total. “The second tranche of convertible notes was subject to the achievement of Phase III data from studies 171 and 175 that met the primary efficacy endpoints of these studies and did not show any adverse safety issue that would reasonably be expected to prevent approval of Afrezza,” MannKind says in a release.

MannKind Corporation (NASDAQ:MNKD)MannKind Corp. Rating Reiterated by Zacks (MNKD) (The Utah People’s Post)
Zacks restated their neutral rating on shares of MannKind Corporation (NASDAQ:MNKD) in a report released on Wednesday, StockRatingsNetwork.com reports. Zacks currently has a $7.25 price objective on the stock. Zacks’ analyst wrote, “MannKind’s second quarter 2013 net loss of $0.16 per share was narrower than the year-ago loss of $0.23 but wider than the Zacks Consensus Estimate of a loss of $0.15. We expect investor focus to remain on Afrezza. MannKind completed both its late-stage studies (Affinity 1 and Affinity 2) on Afrezza and expects results from the studies soon. The company plans to resubmit the NDA for Afrezza later in the year. However, we remain concerned about the company’s over dependence on Afrezza.

MannKind Down 8 Percent on Analyst Downgrade But Traders Point Out a Flaw in the Logic (MNKD) (Breaking Finance News)
Shares of MannKind Corporation (NASDAQ:MNKD) are down more than 8 percent in afternoon trading Friday after an analyst downgrade. According to Seeking Alpha, Summer Street is suspicious of the results of its recently reported AFFINITY trial. Specifically, it said, that MannKind “released results on the injectable insulin and Dreamboat arms but withheld the results on the Medtone C-arm”

MLV Capital Increases MannKind Corp. Price Target to $11.00 (MNKD) (Zolmax)
Equities research analysts at MLV Capital raised their target price on shares of MannKind Corporation (NASDAQ:MNKD) from $8.00 to $11.00 in a research note issued to investors on Thursday, AnalystRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. MLV Capital’s price objective points to a potential upside of 65.66% from the company’s current price. A number of other firms have also recently commented on MNKD. Analysts at JMP Securities downgraded shares of MannKind Corp. from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday.

MannKind Corporation (NASDAQ:MNKD) Continues To Under pressure On High Volume (Market News Call)
Shares of MannKind Corporation (NASDAQ:MNKD) continues to be under pressure and slid another 9% in the opening session despite the company said that it satisfies conditions for second tranche of convertible note financing. Just after the news, the stock was up about 4% in pre-open session. The company announced that, pursuant to a Facility Agreement dated July 1, 2013 between Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) and MannKind, the conditions that obligate Deerfield to purchase the second $40 million tranche of 9.75% senior secured convertible notes (the “Convertible Notes”) have now been satisfied.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!